ArticleVeterinary world2025
Clinical features and hematological and biochemical blood parameters of dogs with hepatobiliary disorders.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Hepatobiliary disorders represent a significant clinical concern in canine medicine, contributing to substantial morbidity and mortality. However, comprehensive data on clinical presentation and hematological and biochemical alterations associated with these disorders in Vietnam remain limited. This study aimed to characterize the clinical manifestations and hematobiochemical profiles of dogs diagnosed with hepatobiliary disorders in Ho Chi Minh City, Vietnam. Materials and Methods: Eighty client-owned dogs diagnosed with hepatobiliary disorders through histopathological confirmation were retrospectively evaluated. Clinical signs, age, breed, and sex were recorded. Hematological indices - including red and white blood cell counts, hemoglobin concentration, hematocrit, and platelet (PLT) count - and biochemical parameters - such as total protein (TP), albumin (ALB), globulin, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), blood urea nitrogen (BUN), creatinine (CREA), and uric acid - were assessed. Data were analyzed using one-way analysis of variance and Pearson's Chi-square test, with statistical significance set at p < 0.05. Results: Hepatitis was the most prevalent disorder (38.8%), followed by biliary disorders, hepatic lipidosis, neoplastic disorders (each 16.3%), and cirrhosis (12.5%). Vomiting (60.0%), jaundice (57.5%), and diarrhea (48.8%) were among the most frequent clinical signs, with significant variability across disorder types (p < 0.05). A significant variation in PLT counts was observed, with the highest values in hepatic lipidosis cases (p = 0.04). Biochemical analysis revealed marked elevations in total bilirubin, ALT, AST, ALP, and GGT across disorders (p < 0.05), particularly in hepatitis and neoplastic cases. Dogs with cirrhosis exhibited significantly reduced TP and ALB concentrations. Elevated BUN and CREA were also noted in dogs with neoplastic conditions, suggesting concurrent renal involvement. Conclusion: This study is the first to delineate the clinical and hematobiochemical characteristics of canine hepatobiliary disorders in Vietnam. The findings underscore the diagnostic value of integrating clinical signs with laboratory indices, particularly elevated liver enzymes and hypoalbuminemia, in the identification and differentiation of hepatobiliary conditions. These insights may enhance clinical decision-making and contribute to improved diagnostic accuracy and therapeutic outcomes in veterinary hepatology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.